MedTrace Logo

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00099242 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1040

Last updated 2017-10-13

No results posted yet for this study

Summary

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Conditions

Interventions

DRUG

rivastigmine transdermal patch

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2006-01-31

Countries

  • United States
  • Chile
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Guatemala
  • Israel
  • Italy
  • Mexico
  • Norway
  • Peru
  • Poland
  • Portugal
  • Puerto Rico
  • Russia
  • Slovakia
  • South Korea
  • Sweden
  • Taiwan
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00099242 on ClinicalTrials.gov